Trial Profile
A Phase 1 Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Adebrelimab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jiangsu Hengrui Medicine Co.
- 13 Sep 2022 Results(n=41) assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy in patients with advanced solid tumors presented at the 47th European Society for Medical Oncology Congress
- 27 Mar 2018 New trial record